RainDance Technologies and Ambry Genetics have launched ADMESeq, a targeted sequencing panel that will sequence 242 genes involved with drug absorption, distribution, metabolism, and excretion.
By Julia KarowThis article has been updated from a previous version to attribute Ambry's comments to the company's assistant medical director.
By a GenomeWeb staff reporter
Ambry Genetics will be the first authorized service provider for a new high-throughput target enrichment system being developed by RainDance Technologies, the companies announced last week.
By Justin Petrone
Growing demand for arrays designed to detect tumor copy-number changes is enticing more chip manufacturers to offer tools tailor-made for cancer research.
Ambry Genetics last week launched its CancerArray, an exon-focused, 180,000-probe array for comparative genomic hybridization.
Ambry's StemArray is manufactured by Roche NimbleGen and enables researchers studying stem cells to detect genomic abnormalities that would ordinarily be missed by low-resolution karyotyping.
CLG will sell the StemArray products and services to its current customers and other companies and research institutions.
Ambry Genetics is now able to offer all Roche NimbleGen applications, the first of Roche NimbleGen's growing list of service providers to achieve such certification.
Ambry is now certified on all Roche NimbleGen applications, offering services from its lab in California.
The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.
An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.
The US Department of Agriculture presents a new blueprint for animal genomic research.
In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.